Why the study?
To summarize recent evidence on the effectiveness and safety of antihypertensive fixed-dose combination medications and describe facilitators and barriers to implementing them in US clinical practice.
Do antihypertensive fixed-dose combination medications improve blood pressure control and cardiovascular outcomes in patients with hypertension?
Do antihypertensive fixed-dose combination medications improve blood pressure control and cardiovascular outcomes in patients with hypertension?
Fixed-dose combination medications for hypertension improve blood pressure control, medication adherence, and cardiovascular outcomes compared to monotherapy, though implementation barriers remain in clinical practice.
PURPOSE OF REVIEW: To summarize the recent evidence on the effectiveness and safety of antihypertensive fixed-dose combination (FDC) medications, and to describe the facilitators and barriers to implementing FDCs in US clinical practice. RECENT FINDINGS: Recent clinical practice guidelines include FDC use for treating high BP. Clinical trials in recent years support the use of antihypertensive FDCs including low-dose triple- and quadruple-therapy FDCs. Initiating a low-to-standard dose dual-therapy FDCs showed better BP control than initiating treatment with a standard-dose monotherapy, and triple-therapy FDCs produced better BP control rates than dual-therapy FDCs. Retrospective cohort studies showed that FDCs are associated with increased medication adherence, reduced clinical inertia, decreased time to BP control, and improved cardiovascular outcomes. We further discussed barriers and facilitators of wider implementation of antihypertensive FDCs in clinical practice. FDC treatment for hypertension is not commonly used despite historical and recent data which support the effectiveness, safety, and benefits of FDCs. Simplified and protocolized treatment algorithms, team-based care, shared decision-making principles are crucial to successful utilization and implementation of FDC in clinical practice.
No takes yet. Share an insight, caveat, or question.
An et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: